Evidence map›Paper›PMID 40214930›Full record

ReviewCurrent cardiology reports2025

Yaqi Zheng, Yanlin Wang, Xiaoli Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Research Progress in Imaging Evaluation of Myocardial Microcirculation.International journal of general medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yaqi ZhengDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yanlin WangDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Xiaoli ZhangDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. xlzhang68@126.com.

Funding

Beijing Natural Science Foundation 7232040National Natural Science Foundation of China 82171994
6 · The paper itself

Abstract

purpose of reviewThe diagnosis of light-chain cardiac amyloidosis (AL-CA) is often delayed owing to nonspecific clinical symptoms and comorbidities, making early detection and risk stratification essential for early intervention. Activated cardiac fibroblasts play a vital role in cardiac remodeling and cardiac damage progression, leading to heart failure. Emerging imaging modalities visualize fibroblast activation protein (FAP) as a marker of activated fibroblasts, enabling non-invasive and accurate measurement of cardiac remodeling for risk stratification. This review summarizes the status of diagnosis and treatment, pathogenic basis of AL-CA, and positron emission tomography (PET) imaging to assess the potential of gallium 68 ( RECENT

findings

Indexed as

CardiomyopathiesImmunoglobulin Light-chain AmyloidosisPositron Emission Tomography Computed TomographyGallium RadioisotopesHumansQuinolinesRadiopharmaceuticalsRisk Assessment68Ga-FAPIGallium RadioisotopesQuinolinesRadiopharmaceuticalsCardiac fibroblastFibroblast activation proteinLight-chain cardiac amyloidosisPET/CT

Identifiers

PMID40214930

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.